Atrial Fibrillation Following Investigation of Rhythm Management: AFFIRM Trial Outcomes. What Might Be Their Implications for Arrhythmia Control?

1. Movsowitz C , Marchlinski FE . Interactions between implantable cardioverter-defibrillators and class III antiar-rhythmic drugs. Am J Cardiol 82:411-411, 1998

2. Prystowsky EN , Benson D , Woodrow M , et al. Management of patients with atrial fibrillation: A statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology, American Heart Association. Circulation 93(6):1262-1277, 1996

3. Jung F , DiMarco JP. MD. Treatment strategies for atrial fibrillation. Am J Med 104(3):272-286

4. Jais P , Haissaguerre M , Shah DC . A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation 95:572-576, 1997

5. Haissaguerre M , Jais P , Shah DC , et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339:659-666, 1998

6. Moe GK , Abildskov JA . Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge. Am Heart J 58:59-70, 1959

7. Moe GK . On the multiple wavelet hypothesis of atrial fibrillation. Arch Int Pharmacodyn Ther 140:183-188, 1962

8. Singh BN , Vaghaiwalla Mody F , Lopez B , Sarma JSM . Antiarrhythmic agents for atrial fibrillation: Focus on prolong atrial repolarization. Am J Cardiol 84:161R-173R, 1999

9. Singh BN . Current antiarrhythmic drugs: An overview of mechanisms of action and potential clinical utility. J Cardiovasc Electrophysiol 10:83-301, 1999

10. Nattel S , Singh BN . Evolution, mechanisms, and classification of antiarrhythmic drugs: Focus on Class III actions. Am J Cardiol 84(9A): 11-19, 1999

11. Lazzara R . From first class to third class: Recent upheaval in antiarrhythmic therapy-lessons from clinical trials. Am J Cardiol 78:28-33, 1996

12 Hohnloser SH , Singh BN . Proarrhythmia with class III antiarrhythmic drugs. Definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol 6:920-936, 1995

13. Singh BN . Antiarrhythmic actions of amiodarone: A profile of a paradoxical agent. Am J Cardiol 78:41-53, 1996

14. Singh BN . What niche will newer class III antiarrhythmic drugs occupy? Current Cardiology Reports 3:314-323, 2001

15. Roy D , Talajic M , Dorian P , et al, for the Canadian Trial of Atrial Fibrillation Investigators. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 342:913-918, 2000

16. The AFFIRM Investigators . Atrial fibrillation following investigation of rhythm management: AFFIRM Study Design. Am J Cardiol 79:1198-1204, 1997

17. Mason JW , ESVEM Investigators . A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 329:452-462, 1993